Business Context and Reporting Period
This Form 8-K filing by LIFECORE BIOMEDICAL, INC. (LFCR) was submitted on August 22, 2023, reporting an event that occurred on August 17, 2023. The Company is a Delaware corporation with its principal executive offices in Chaska, Minnesota, and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding regulatory compliance and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Events
- Nasdaq Delisting Notice: On August 17, 2023, the Company received a notification from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to a delay in filing its Annual Report on Form 10-K for the period ended May 28, 2023.
- Trading Status: The notification has no immediate effect on the listing or trading of the Company's common stock.
- Compliance Timeline: The Company has 60 calendar days (until October 16, 2023) to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 calendar days from the original due date (until February 12, 2024) to file the Form 10-K.
Outlook, Risks, and Management Commentary
Management states the Company is working diligently to complete the Form 10-K and plans to file it as promptly as possible. The filing includes a cautionary note regarding forward-looking statements, highlighting specific risks:
- The ability to respond timely to Nasdaq inquiries.
- The ability to regain compliance with the Listing Rule.
- The ability to become current with SEC reports.
- The risk that the completion and filing of the Form 10-K will take longer than expected.
Investor Verification Checklist
- Verify the status of the Form 10-K for the period ended May 28, 2023, and whether it has been filed.
- Monitor the Company's submission of a compliance plan to Nasdaq by the October 16, 2023 deadline.
- Review the Company's most recent Annual Report on Form 10-K/A for detailed risk factors not fully elaborated in this 8-K.
- Confirm whether the Company has received approval from Nasdaq for an extended compliance period.